Yacine Ouadi, Ksontini Feryel Letaief, Ben Mahmoud Ahmed, Magherbi Houcine, Fterich Samir Fadhel, Kacem Montasser
Department of Surgery, A La Rabta, Tunis, Tunisia.
Faculty of Medicine of Tunis, Tunis El Manar University, Tunis, Tunisia.
Ann Med Surg (Lond). 2022 Apr 9;77:103604. doi: 10.1016/j.amsu.2022.103604. eCollection 2022 May.
Glucagonoma is a rare neuroendocrine tumor (NET). Most glucagonomas are in the tail or body of the pancreas and are diagnosed at a metastatic stage. We report a case of an early recurrence after surgical resection of a glucagonoma and its management.
We present a case of a 44-year-old female patient with no medical and surgical history, operated on in May 2018 for pancreatic glucagonoma revealed by skin necrolytic migratory erythema. The patient was regularly monitored by clinical exams and CT scans. In December 2020 (31 months postoperatively), we noticed the recurrence of the cutaneous lesions.Admission laboratory measurements demonstrated hyperglycemia as well as elevated blood Glucagon levels. Explorations showed 3 retro-pancreatic lesions. Based on these findings, we concluded that it was a recurrence of her glucagonoma. The patient was operated on by median laparotomy We performed a warshow's procedure.Pathology confirmed the endocrine nature of the 3 nodules. We are currently 6 months behind the surgery. The examination is strictly normal with no recurrence of the skin lesions so far.
Surgical resection on a recurrent glucagonoma is what is unique in our case as we haven't found any case in the literature to our knowledge.What is also unique about our case is both the local aspect of the recurrence and the multiplicity of the tumors observed as multiple nodules around the tail of the pancreas. These lesions were not metastatic lymph nodes as confirmed by pathology. Probably it was an effraction of the big tumor at enucleation.
Due to its rareness, there is no clear consensus on the management of glucagonomas therefore we chose to write our case in order to further enrich the literature to achieve one-day guidelines for glucagonomas treatment.
胰高血糖素瘤是一种罕见的神经内分泌肿瘤(NET)。大多数胰高血糖素瘤位于胰腺尾部或体部,在转移阶段被诊断出来。我们报告一例胰高血糖素瘤手术切除后早期复发及其处理的病例。
我们呈现一名44岁女性患者,无内科及外科病史,于2018年5月因皮肤坏死性游走性红斑发现胰腺胰高血糖素瘤而接受手术。患者通过临床检查和CT扫描定期监测。2020年12月(术后31个月),我们注意到皮肤病变复发。入院实验室检查显示血糖升高以及血胰高血糖素水平升高。检查发现胰腺后方有3个病变。基于这些发现,我们得出这是她的胰高血糖素瘤复发。患者接受了正中剖腹手术,我们进行了Warshow手术。病理证实这3个结节具有内分泌性质。目前我们距离手术已有6个月。检查结果完全正常,到目前为止皮肤病变未复发。
复发性胰高血糖素瘤的手术切除是我们病例中的独特之处,据我们所知在文献中未发现类似病例。我们病例的另一个独特之处在于复发的局部情况以及观察到的肿瘤多发性,表现为胰腺尾部周围的多个结节。病理证实这些病变不是转移性淋巴结。可能是在摘除大肿瘤时发生了破裂。
由于其罕见性,对于胰高血糖素瘤的治疗尚无明确共识,因此我们选择撰写我们的病例,以便进一步丰富文献,以形成未来胰高血糖素瘤治疗的指南。